DiscGenics
UT - Salt Lake CityBiotechnology
Focus: DiscGenics is a private biotechnology company founded in 2008 specializing in spinal stem cell therapies for degenerative disc disease and musculoskeletal conditions. The company is early-stage with a focused pipeline centered on its lead candidate IDCT.
Profile data last refreshed 6h ago · AI intelligence enriched 2w ago
Funding Stage
PRIVATE
Open Jobs
3
Should You Work at DiscGenics?
AI assessmentDiscGenics is a high-risk, high-reward early-stage bet suited to cell therapy specialists seeking equity upside and operational hands-on experience, but cash position and funding visibility are critical pre-interview questions.
Why Work Here
- Opportunity to work on novel cell therapy modality in a high-unmet-need musculoskeletal space with Phase 3 program advancing toward potential clinical validation.
Data completeness
3/9 — Basic
Company HealthStrong
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
PHASE_1
Clinical Trials (1)
NCT03347708Study to Evaluate the Safety and Preliminary Efficacy of IDCT, a Treatment for Symptomatic Lumbar Intervertebral Disc Degeneration
Phase 1Help build intelligence for DiscGenics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.